Vecuronium

Class Non-depolarising NMJ blocker
Chemistry

Aminosteroid

Routes of administration

IV or IM only

Absorption

Poor absorption; minimal oral bioavailability

Solubility

pKa=8.97; good water solubility

Distribution

VOD= 0.2L/kg, 77% protein-bound

Metabolism

Perthaps 5% is metabolised; one of the metabolites has about 80% of the potency of the parent drug (3-desacetylvecuronium)

Elimination

30-40% is cleared by the liver and into the bile (good lipid solubility); another 30% is renally eliminated as iunchanged drug

Time course of action

Half-life 110 minutes

Target receptor

Nicotinic acetylcholine receptors at the neuromuscular junction

Mechanism of action

Nondepolarising neuromuscular junction blocker (competitive antagonist of acetylcholine); by binding to the nicotinic acetylcholine receptor, this agent blocks the binding of acetylcholine, and prevents the cation channel from opening, thus preventing the depolarisation of the motor endplate.

Clinical effects

Nondepolarising neuromuscular junction blockade; also:
- Minimal ganglionic effects
- Minimal vagolytic effect (slight increase in HR)
- Minimalsympathomimetic effect (slight increase in HR)
- Minimal histamine release (only slightly more than pancuronium)

Literature reference

Miller et al (1984)

CICM details of understanding Level 2
Mentioned around Deranged Physiology
Related SAQs

Question 6 from the first paper of 2021 (vecuronium)

Question 19 from the first paper of 2023 (prolonged block, and vecuronium)